Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Shiraz University of Medical Sciences | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to evaluate the effect of vitamin E fortified whey drink on nutritional status, inflammatory markers and oxidative stress in hemodialysis patients
The aim of this interventional study was to evaluate the effect of vitamin E fortified whey drink on nutritional status, inflammatory markers and oxidative stress in hemodialysis patients. 92 hemodialysis patients were selected for the study. Inclusion criteria included: mean age of 17-65 years old; having mild, moderate or severe malnutrition based on the SGA (subjective global assessment) assessment; being dialyzed at least 2 times a week for 3 months. Exclusion criteria included: hospitalization in the last month; active infection; using immunosuppressant drugs or multi-vitamins; pregnancy. The Ethics Committee of Shiraz University of Medical Sciences reviewed and approved the protocol of this study.Informed consent were signed by all of them for participating in the study. Weight and height of the patients were recorded for BMI (body mass index) calculation. Then, all of the patients were assigned into 4 groups:
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| whey drink | Experimental | consumption of 220 milliliters of whey drink three times a week, |
|
| whey drink fortified with vitaminE | Experimental | consumption of 220 milliliters of whey drink fortified with 400 milligrams of vitamin E three times a week, |
|
| vitaminE | Experimental | consumption of 400 milligrams of vitamin E three times a week, |
|
| D- control | No Intervention | control group: no intervention, |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| whey drink, | Dietary Supplement | consumption of 220 milliliters of whey drink three times a week, |
|
| Measure | Description | Time Frame |
|---|---|---|
| malnutrition (based on SGA assessment) | 2 months (8 weeks) | |
| Malnutrition inflammation score | 2 months (8 weeks) |
| Measure | Description | Time Frame |
|---|---|---|
| serum interleukin-6 | 2 months (8 weeks) | |
| serum C-reactive protein | 2 months (8 weeks) | |
| serum albumin |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mohammad Hassan Eftekhari, professor | Shiraz University of Medical Sciences | Study Director |
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 32390133 | Derived | Mah JY, Choy SW, Roberts MA, Desai AM, Corken M, Gwini SM, McMahon LP. Oral protein-based supplements versus placebo or no treatment for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev. 2020 May 11;5(5):CD012616. doi: 10.1002/14651858.CD012616.pub2. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D051436 | Renal Insufficiency, Chronic |
| D044342 | Malnutrition |
| ID | Term |
|---|---|
| D051437 | Renal Insufficiency |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D014810 | Vitamin E |
| ID | Term |
|---|---|
| D001578 | Benzopyrans |
| D011714 | Pyrans |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| whey drink fortified with vitaminE | Dietary Supplement | consumption of 220 milliliters of whey drink fortified with 400 milligrams of vitamin E three times a week, |
|
| vitamin E | Dietary Supplement | consumption of 400 milligrams of vitamin E three times a week, |
|
| 2 months (8 weeks) |
| serum HDL-c | 2 months (8 weeks) |
| serum total cholesterol | 2 months (8 weeks) |
| serum triglyceride | 2 months (8 weeks) |
| serum transferrin | 2 months (8 weeks) |
| serum malondialdehyde | 2 months (8 weeks) |
| BUN (blood urea nitrogen) | 2 months (8 weeks) |
| serum creatinine | 2 months (8 weeks) |
| serum calcium | 2 months (8 weeks) |
| serum phosphate | 2 months (8 weeks) |
| quality of life | 2 months (8 weeks) |
| weight | 2 months (8 weeks) |
| height | 2 months (8 week) |
| Body mass index | 2 months (8 weeks) |
| D005261 |
| Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
| D006574 |
| Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |